Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 8/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605648 | 0.96 | ADRB1 (0.64) | ADRB1HTR2CDRD2PRKCIPRKCZ | |
| Hydrochloric Acid SCHEMBL9100885 | 0.95 | ADRB1 (0.63) | ADRB1HTR2CDRD2PRKCIPRKCZ | |
| SCHEMBL9884105 | 0.89 | ADRB1 (0.53) | ADRB1HRH4 | |
| SCHEMBL602746 | 0.84 | HRH4 (0.54) | ADRB1PRKCIPRKCZHRH4HRH3 | |
| SCHEMBL603906 | 0.83 | HRH4 (0.53) | ADRB1PRKCIPRKCZHRH4HRH3 | |
| SCHEMBL604631 | 0.82 | ADRB1 (0.50) | ADRB1HTR2CHRH4HRH3GUSB | |
| SCHEMBL604915 | 0.81 | ADRB1 (0.49) | ADRB1PRKCIPRKCZHRH4 | |
| SCHEMBL9883820 | 0.81 | ADRB1 (0.46) | ADRB1HTR2CDRD2PRKCIPRKCZ | |
| SCHEMBL601988 | 0.81 | ADRB1 (0.49) | ADRB1PRKCIPRKCZHRH4 | |
| Hydrochloric Acid SCHEMBL4131473 | 0.81 | ADRB1 (0.49) | ADRB1HTR2CHRH4HRH3GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200595-B1 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | claimed |
| US-8445482-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-21 | — | — | US | claimed |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-10-25 | — | — | US | claimed |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós i | 2012-09-20 | — | — | US | claimed |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-08-23 | — | — | US | claimed |
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós | 2012-08-16 | — | — | US | claimed |
| EP-2200595-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-06-30 | — | — | EP | claimed |
| WO-2009038673-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-26 | — | — | WO | claimed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009038673-A2 | THIENO-AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 351/4885HTR2C 61/4885DRD2 928/4885 |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | ADRB1 351/4885HTR2C 61/4885DRD2 928/4885 |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 351/4885HTR2C 61/4885DRD2 928/4885 |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 248/4885HTR2C 65/4885DRD2 803/4885 |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | ADRB1 351/4885HTR2C 61/4885DRD2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.